Dipeptidyl-Peptidase IV Inhibitors: all 899 studies that test it
Page 5 of 9. Open to participants first (28), then studies with results posted, then the rest; newest registration first within each.
- Empagliflozin Versus Vildagliptin in CAD Patients With T2DMCompletedNCT06313008Not applicable
- Bioequivalence Study to Compare Metformin / Vildagliptin (850 mg/50 mg) Versus Galvumet®CompletedNCT06103747Phase 1
- Vildagliptin Versus Glimepiride in Type 2 Diabetic PatientsCompletedNCT06068686Not applicable
- Feasibility of DPP-4 Inhibitor Therapy on Advanced Hybrid Closed Loop SystemCompletedNCT06021119Phase 3
- Effect of Sitagliptin on Polycystic Ovarian Syndrome PatientsCompletedNCT05972928Phase 2/3
- High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHDWithdrawnNCT05895201Phase 1/2
- A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers in Fed ConditionCompletedNCT05874180Phase 1
- A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult VolunteersCompletedNCT05874167Phase 1
- Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 DiabetesStatus unknownNCT05663736Phase 4
- SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)CompletedNCT05579119Phase 4
- Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and MetforminCompletedNCT05504239Phase 3
- Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and MetforminCompletedNCT05504226Phase 3
- Non-alcoholic Fatty Liver Disease and Its TreatmentCompletedNCT05480007Not applicable
- Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 DiabetesStatus unknownNCT05473806Phase 4
- A Pharmacokinetic Study of DW6012 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult VolunteersCompletedNCT05403281Phase 1
- Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes MellitusCompletedNCT05359432Phase 4
- Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?CompletedNCT05359341Not applicable
- The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune ThrombocytopeniaStatus unknownNCT05353673Phase 2
- The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safeyt Profile of Test Product Compared to Reference Product Will be Assessed.CompletedNCT05329844Not applicable
- LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 DiabetesCompletedNCT05313529Not applicable
- Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes MellitusCompletedNCT05290506Phase 3
- Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single ComponentsCompletedNCT05266404Phase 1
- Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary SyndromeStatus unknownNCT05200793Phase 4
- Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes PatientsCompletedNCT05167513Phase 4
- A Study to Evaluate the Effect of Different Meal Types on the Pharmacokinetics of DBPR108 in Healthy SubjectsCompletedNCT05150626Phase 1
- A Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of DBPR108 Tablets in Type 2 Diabetes Mellitus PatientsCompletedNCT05146869Phase 1
- A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)TerminatedNCT05143177Phase 2/3
- Mass Balance and Biotransformation Study of [14C]DBPR108 in HumanCompletedNCT05072028Phase 1
- A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy SubjectsCompletedNCT05045313Phase 1
- Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver TransplantationCompletedNCT05042505Not applicable
- Comparison of the FGM Profiles in Patients of Type 2 Diabetes Treated With Sitagliptin and AcarboseCompletedNCT05035849Not applicable
- ORAL ANTIDIABETICS EFFECT ON VISCERAL FATStatus unknownNCT05032001Not applicable
- Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 DiabetesCompletedNCT04916093Phase 4
- Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese SubjectsCompletedNCT04877106Phase 1
- A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy SubjectsCompletedNCT04859452Phase 1
- A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal ImpairmentCompletedNCT04859439Phase 1
- A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic ImpairmentCompletedNCT04859426Phase 1
- Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment FailureCompletedNCT04841096Phase 3
- Vildagliptin for Treatment of Antipsychotic-induced DyslipidemiaWithdrawnNCT04761861Phase 2
- A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and DapagliflozinStatus unknownNCT04706637Phase 4
- Gemigliptin and Biomarkers of Kidney Injury and Vascular CalcificationCompletedNCT04705506Not applicable
- DPP4 Inhibitor on Glycemic VariabilityCompletedNCT04654676Phase 4
- A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mgStatus unknownNCT04653779Phase 4
- Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19CompletedNCT04542213Phase 3
- Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVDStatus unknownNCT04521452Phase 4
- Tubular Markers in Response to Saxagliptin TherapyCompletedNCT04521049Phase 4
- Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications ProgressionStatus unknownNCT04485845Phase 4
- Glimepiride, Alogliptin and Alogliptin+Pioglitazone CombinationStatus unknownNCT04470310Phase 4
- Sitagliptin for the Treatment of Grade 3-4 and Refractory Acute Graft-versus-host DiseaseStatus unknownNCT04448587Phase 2
- A Randomized, Placebo-controlled Clinical Trial of Teneligliptin as Quadruple Oral Combination Therapy for Type 2 DM After Failure of an Oral Triple Anti-diabetic RegimenCompletedNCT04446026Phase 4
- Pharmacokinetic Drug Interaction Between Teneligliptin and EmpagliflozinCompletedNCT04431141Phase 1
- The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder PatientsWithdrawnNCT04410341Phase 1/2
- Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist StudyCompletedNCT04409795Phase 2/3
- Anti-inflammatory Status in DM2 Treated PatientsStatus unknownNCT04392557Phase 4
- Dose Modification Requirement for Trelagliptin in Egyptian PopulationStatus unknownNCT04374864Phase 4
- Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19TerminatedNCT04371978Phase 3
- Omarigliptin in Four Healthy Egyptian VolunteersStatus unknownNCT04365907Not applicable
- The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic PatientsStatus unknownNCT04365517Phase 3
- Effects of DPP4 Inhibition on COVID-19WithdrawnNCT04341935Phase 4
- Effects of Sitagliptin in Individuals With Genetically Decreased DPP4Active, not recruitingNCT04323189Phase 4
- Bioequivalence Study for Fixed Dose Combination Zemimet® SR Tab. 50/1000 and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.CompletedNCT04317703Phase 1
- Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)CompletedNCT04304261Phase 3
- Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic AgentsStatus unknownNCT04287387Phase 4
- Comparing the Effect of Sitagliptin/Metformin and Metformin in PCOS PatientsStatus unknownNCT04268563Phase 1/2
- A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin AloneStatus unknownNCT04255238Phase 3
- Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During RamadanCompletedNCT04237493Phase 4
- A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DMCompletedNCT04218734Phase 3
- The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis PatientsCompletedNCT04195919Phase 1
- Study of Sulphonylurea Synergy With DPP4 InhibitorsCompletedNCT04192292Not applicable
- Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic ControlCompletedNCT04170998Phase 3
- Evaluation of Drug Interactions of Saxagliptin With Sildenafil in Healthy VolunteersStatus unknownNCT04170790Not applicable
- Effect of Low Dose Combination of Linagliptin + Metformin to Prevent DiabetesStatus unknownNCT04134650Phase 3
- Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With PrediabetesStatus unknownNCT04131582Phase 3
- Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With MetformineCompletedNCT04088461Phase 4
- Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon SecretionCompletedNCT04061473Not applicable
- Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVDCompletedNCT04055883Phase 2
- Bioequivalence Study for Gemigliptin/Metformin 50/1000 mg and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.Status unknownNCT04050098Phase 1
- Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and SulfonylureasCompletedNCT03983551Phase 4
- Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 DiabetesCompletedNCT03940183Phase 3
- Neuropeptide Y and Sympathovagal BalanceCompletedNCT03933787Early Phase 1
- Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver DiseasesCompletedNCT03910361Phase 4
- Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 DiabetesCompletedNCT03893526Phase 4
- An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)CompletedNCT03864432Phase 1
- GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic PolypeptideCompletedNCT03845179Not applicable
- A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)CompletedNCT03842267Phase 3
- Vildagliptin in Older Adults With Diabetes and Mild Cognitive ImpairmentCompletedNCT03819127Phase 4
- Approaches To Therapy Escalation In T2DWithdrawnNCT03813316Phase 4
- Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug NaiveCompletedNCT03794336Phase 4
- Drug Interaction Study Between Dorzagliatin and SitagliptinCompletedNCT03790839Phase 1
- A Study to Compare MP-513 20mg & Metformin XR 1000mg FDC With Coadministration of the Two Separate DrugsCompletedNCT03787017Phase 1
- Teneligliptin and Atorvastatin DDI StudyCompletedNCT03769870Phase 1
- The Effects of Neprilysin on Glucagon-like Peptide-1CompletedNCT03717688Phase 4
- Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.CompletedNCT03714594Phase 2
- Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CADCompletedNCT03693560Phase 4
- Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal InsufficiencyCompletedNCT03667300Phase 2
- Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes MellitusCompletedNCT03659461Not applicable
- Efficacy and Safety of Empagliflozin in NODATTerminatedNCT03642184Phase 4
- Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 DiabetesStatus unknownNCT03602638Phase 4
- Gemigliptin, Dapagliflozin, Empagliflozin DDI StudyStatus unknownNCT03565458Phase 1
- Tenelia Elderly CGMS Study(TEDDY)CompletedNCT03508323Phase 4